Gilead Sciences: 3rd trial impressive against HIV/AIDS
Gilead Sciences, Inc. (NASDAQ ticker: GILD) is a force to reckon with in the biopharmaceutical field in America.
Currently headquartered in Foster City, California, Gilead has done extensive research and innovation work towards developing antiviral drugs that are being used in the treatment of HIV/AIDS and other life-threatening diseases such as Hepatitis.
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
Lenacapavir is the injection from Gilead Sciences giving hope to HIV/AIDS patients
It is reported that the Lenacapavir injection developed by Gilead Sciences, Inc. prevented HIV cases in both adolescent and adult women in Africa. This has been a successful Phase 3 trial.
It is also reported that none of the roughly two thousand females who received the Lenacapavir injection contracted HIV during the active period.
With Lenacapavir injection, patients may have to switch from taking daily pills to enjoying the longer-active injection from GILD. This has been quite the innovation that has taken the biotech world by storm.
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
Interesting things to know about Gilead Sciences, Inc. (GILD)
Exchange: NASDAQ, USA
Sector: Health
Industry: Biotechnology
Market Cap: 88.62 million dollars (US)
Earnings Per Share (EPS): $4.66
Next dividend payout date: June 27th, 2024
Gilead Sciences, Inc. (GILD) is currently priced at $71.22 per share as at time of writing. With an annual low of $62.07 and 52 week high of $87.86, GILD is poised to do more amazing work in the global biopharmaceutical industry.
If you’re living in Nigeria, you can own Gilead Shares when you sign up here.
Uncle Wealth
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
>> Click here to signup and buy Gilead Sciences shares from Nigeria <<
PS:
The information presented herein is only for informational purposes. Please contact a competent stock broker for stock market investment advice.
Uncle Wealth Community: Boys, click here to join
Hire me to write for you? Or chat with me?
Whatsapp: Click here to send me a message
Email: prosperbwealth@gmail.com
